Literature DB >> 24160673

Quantifying under-reporting of pathology tests in Medical Benefits Schedule claims data.

Judy A Trevena1, Kris D Rogers, Louisa R Jorm, Tim Churches, Bruce Armstrong.   

Abstract

OBJECTIVE: We investigated the completeness of recording of pathology tests in Australian Medical Benefits Schedule (MBS) claims data, using the example of the prostate-specific antigen (PSA) test. With some exceptions, MBS claims data records only the three most expensive pathology items in an episode of care, and this practice ('episode coning') means that pathology tests can be under-recorded.
METHODS: The analysis used MBS data for male participants in the 45 and Up Study. The number and cost of items in each episode of care were used to determine whether an episode contained a PSA screening test (Item 66655), or could have lacked a record of this item because of episode coning.
RESULTS: MBS data for 1070392 episodes involving a request for a pathology test for 118074 men were analysed. Of these episodes, 11% contained a request for a PSA test; a further 7.5% may have been missing a PSA request that was not recorded because of episode coning.
CONCLUSIONS: It is important to consider under-reporting of pathology tests as a result of episode coning when interpreting MBS claims data. Episode coning creates uncertainty about whether a person has received any given pathology test. The extent of this uncertainty can be estimated by determining the proportion of episodes in which the test may have been performed but was not recorded due to episode coning.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24160673     DOI: 10.1071/AH13092

Source DB:  PubMed          Journal:  Aust Health Rev        ISSN: 0156-5788            Impact factor:   1.990


  7 in total

1.  Empirical evidence of recall bias for primary health care visits.

Authors:  Natasha Kareem Brusco; Jennifer J Watts
Journal:  BMC Health Serv Res       Date:  2015-09-15       Impact factor: 2.655

2.  Doctors' perspectives on PSA testing illuminate established differences in prostate cancer screening rates between Australia and the UK: a qualitative study.

Authors:  Kristen Pickles; Stacy M Carter; Lucie Rychetnik; Vikki A Entwistle
Journal:  BMJ Open       Date:  2016-12-05       Impact factor: 2.692

3.  Thinking Style as a Predictor of Men's Participation in Cancer Screening.

Authors:  Clare E McGuiness; Deborah Turnbull; Carlene Wilson; Amy Duncan; Ingrid H Flight; Ian Zajac
Journal:  Am J Mens Health       Date:  2016-12-05

4.  Factors associated with prostate specific antigen testing in Australians: Analysis of the New South Wales 45 and Up Study.

Authors:  Visalini Nair-Shalliker; Albert Bang; Marianne Weber; David E Goldsbury; Michael Caruana; Jon Emery; Emily Banks; Karen Canfell; Dianne L O'Connell; David P Smith
Journal:  Sci Rep       Date:  2018-03-09       Impact factor: 4.379

5.  Patterns and trends of potentially inappropriate high-density lipoprotein cholesterol testing in Australian adults at high risk of cardiovascular disease from 2008 to 2014: analysis of linked individual patient data from the Australian Medicare Benefits Schedule and Pharmaceutical Benefits Scheme.

Authors:  Farshid Hajati; Evan Atlantis; Katy J L Bell; Federico Girosi
Journal:  BMJ Open       Date:  2018-03-08       Impact factor: 2.692

6.  Microbiology testing associated with antibiotic dispensing in older community-dwelling adults.

Authors:  Zhuoxin Peng; Andrew Hayen; Martyn D Kirk; Sallie Pearson; Allen C Cheng; Bette Liu
Journal:  BMC Infect Dis       Date:  2020-04-25       Impact factor: 3.090

7.  Diagnostic and health service pathways to diagnosis of cancer-registry notified cancer of unknown primary site (CUP).

Authors:  Andrea L Schaffer; Sallie-Anne Pearson; Oscar Perez-Concha; Timothy Dobbins; Robyn L Ward; Marina T van Leeuwen; Joel J Rhee; Maarit A Laaksonen; Glynis Craigen; Claire M Vajdic
Journal:  PLoS One       Date:  2020-03-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.